Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 4/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | APEX1 | P27695 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | PGK1 | P00558 | 1/20 | 0.33 |
| ▸ | PGK2 | P07205 | 1/20 | 0.33 |
| ▸ | ESRRG | P62508 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8149759 | 0.83 | PTPN1 (0.46) | FDPSMEN1KMT2AALDH1A1POLB | |
| SCHEMBL11029750 | 0.78 | PTPRC (0.43) | MEN1KMT2AALDH1A1MAPTPOLB | |
| SCHEMBL8149509 | 0.72 | PGK1 (0.43) | FDPSMEN1KMT2APGK1PGK2 | |
| SCHEMBL4094823 | 0.70 | FDPS (0.53) | FDPSPTGS1MEN1KMT2AMAPT | |
| Water SCHEMBL5163400 | 0.69 | FDPS (0.52) | FDPSPTGS1MEN1KMT2AMAPT | |
| SCHEMBL15187676 | 0.69 | FDPS (0.47) | FDPSEPHX2PTGS1MEN1KMT2A | |
| SCHEMBL2637396 | 0.69 | FDPS (0.47) | FDPSEPHX2PTGS1MEN1KMT2A | |
| SCHEMBL8154833 | 0.68 | PGK1 (0.40) | PGK1PGK2PTPN5 | |
| SCHEMBL2030830 | 0.68 | FDPS (0.47) | FDPSEPHX2PTGS1ALDH1A1CYP1A2 | |
| Trimethylammonium SCHEMBL27751864 | 0.68 | FDPS (0.47) | FDPSEPHX2PTGS1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250375529-A1 | PHOSPHORYLCHOLINE-TUFTSIN CONJUGATE FOR TREATING OCULAR INFLAMMATION | Tarsier Pharma Ltd (IL) | 2025-12-11 | — | — | US | claimed |
| EP-2953978-B1 | PHOSPHORYLCHOLINE CONJUGATES AND USES THEREOF | TPCERA LTD (IL) | 2024-10-23 | — | — | EP | claimed |
| WO-2024028192-A1 | USE OF CONJUGATES OF HUMAN SERUM ALBUMIN AND PHOSPHOCHOLINE FOR BLOCKING C-REACTIVE PROTEIN | PENTRACOR GMBH (DE) | 2024-02-08 | — | — | WO | claimed |
| US-20230338461-A1 | PHOSPHORYLCHOLINE CONJUGATES AND USES THEREOF | TPCERA LTD. (IL) | 2023-10-26 | — | — | US | claimed |
| US-11696935-B2 | Phosphorylcholine conjugates and uses thereof | TPCERA LTD. (IL) | 2023-07-11 | — | — | US | claimed |
| US-11458186-B2 | Phosphorylcholine conjugates and uses thereof | TPCERA LTD. (IL) | 2022-10-04 | — | — | US | claimed |
| US-20210161992-A1 | PHOSPHORYLCHOLINE CONJUGATES AND USES THEREOF | TPCERA LTD. (IL) | 2021-06-03 | — | — | US | claimed |
| US-20210069284-A1 | PHOSPHORYLCHOLINE CONJUGATES AND USES THEREOF | TPCERA LTD. (IL) | 2021-03-11 | — | — | US | claimed |
| US-10842844-B2 | Phosphorylcholine conjugates and uses thereof | TPCERA LTD. (IL) | 2020-11-24 | — | — | US | claimed |
| US-20180353566-A1 | PHOSPHORYLCHOLINE CONJUGATES AND USES THEREOF | TPCERA LTD. (IL) | 2018-12-13 | — | — | US | claimed |
| US-9987372-B2 | Phosphorylcholine conjugates and uses thereof | TPCERA LTD. (IL) | 2018-06-05 | — | — | US | claimed |
| US-20250375529-A1 | PHOSPHORYLCHOLINE-TUFTSIN CONJUGATE FOR TREATING OCULAR INFLAMMATION | Tarsier Pharma Ltd (IL) | 2025-12-11 | — | — | US | disclosed |
| US-12390569-B2 | Simplified regeneration of apheresis columns | PENTRACOR GMBH (DE) | 2025-08-19 | — | — | US | disclosed |
| US-12350308-B2 | Phosphorylcholine conjugates and uses thereof | TPCERA LTD. (IL) | 2025-07-08 | — | — | US | disclosed |
| US-20250186535-A1 | OPHTALMIC COMPOSITIONS AND METHODS OF USING SAME | TARSIER PHARMA LTD. (IL) | 2025-06-12 | — | — | US | disclosed |
| WO-2014122646-A1 | PHOSPHORYLCHOLINE CONJUGATES AND USES THEREOF | TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD. (IL) | 2014-08-14 | — | — | WO | disclosed |
| EP-1962923-B1 | USE OF A MATRIX FOR REMOVING C-REACTIVE PROTEIN FROM BIOLOGICAL LIQUIDS | PENTRACOR GMBH (DE) | 2013-05-01 | — | — | EP | disclosed |
| EP-1962923-A1 | USE OF A MATRIX FOR REMOVING C-REACTIVE PROTEIN FROM BIOLOGICAL LIQUIDS | BETA V3 GmbH (DE) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007076844-A1 | USE OF A MATRIX FOR REMOVING C-REACTIVE PROTEIN FROM BIOLOGICAL LIQUIDS | BETA V3 GMBH (DE) | 2007-07-12 | — | — | WO | disclosed |
| US-5003065-A | Phosphorus-containing Benzo Crown Ethers | STATE UNIVERSITY OF NEW YORK, STATE UNIVERSITY PLAZA, A CORP OF NY. | 1991-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250186535-A1 | OPHTALMIC COMPOSITIONS AND METHODS OF USING SAME | PHOSPHO1, PDE6C, CHKA | FDPS 4273/4885EPHX2 2000/4885PTGS1 991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.